GlassScriptPhysician profile
Kashyap B Patel
NPI 1306899422
$4,178.20
in general payments reported to CMS, 2019-2025
35 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $422 · 2021: $739 · 2022: $622 · 2023: $431 · 2024: $744 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $516.87 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Amgen INC. | $501.03 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $364.46 | 2019-2021 | |
| Pfizer INC. | $293.91 | 2019-2025 | |
| Biotronik INC. | $229.00 | 2022-2023 | Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $216.49 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $197.66 | 2019-2025 | Eliquis, Camzyos |
| Livanova USA, INC. | $191.10 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Actelion Pharmaceuticals US, INC. | $155.12 | 2023-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $151.67 | 2024-2025 | Inspire |
| Novo Nordisk INC | $150.24 | 2021-2022 | |
| Medtronic Vascular, INC. | $138.33 | 2020 | |
| Stemline Therapeutics INC. | $122.45 | 2025 | Orserdu |
| Eisai INC. | $107.22 | 2024 | |
| Cleerly, INC. | $107.04 | 2025 | Cleerly Labs, Cleerly Ischemia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $89.52 | 2019-2022 | |
| Esperion Therapeutics, INC. | $78.46 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $57.80 | 2021 | |
| Edwards Lifesciences Corporation | $51.54 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lantheus Medical Imaging, INC. | $50.14 | 2019-2021 | |
| Abiomed | $46.23 | 2025 | |
| Chiesi USA, INC. | $42.37 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.56 | 2021 | |
| Atricure, INC. | $40.90 | 2023 | |
| Emd Serono, INC. | $34.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $33.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.58 | 2021 | |
| Lundbeck LLC | $23.53 | 2025 | Rexulti |
| Abbott Laboratories | $22.51 | 2020 | |
| Siemens Medical Solutions USA, INC. | $21.05 | 2022 | |
| Celltrion USA INC. | $19.63 | 2024 | Vegzelma |
| Neurelis, INC. | $17.40 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.41 | 2021 | |
| Janssen Scientific Affairs, LLC | $10.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashyap Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.